000135951 001__ 135951
000135951 005__ 20240229105047.0
000135951 0247_ $$2doi$$a10.3390/ijms19030900
000135951 0247_ $$2pmid$$apmid:29562656
000135951 0247_ $$2pmc$$apmc:PMC5877761
000135951 0247_ $$2ISSN$$a1422-0067
000135951 0247_ $$2ISSN$$a1661-6596
000135951 037__ $$aDKFZ-2018-00688
000135951 041__ $$aeng
000135951 082__ $$a570
000135951 1001_ $$0P:(DE-HGF)0$$aCao, Xue$$b0$$eFirst author
000135951 245__ $$aEvaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals.
000135951 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2018
000135951 3367_ $$2DRIVER$$aarticle
000135951 3367_ $$2DataCite$$aOutput Types/Journal article
000135951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1530529225_2274
000135951 3367_ $$2BibTeX$$aARTICLE
000135951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000135951 3367_ $$00$$2EndNote$$aJournal Article
000135951 520__ $$aBreast cancer (BC) is the most common cancer among women and has high mortality rates. Early detection is supposed to be critical for the patient's prognosis. In recent years, several studies have investigated global DNA methylation profiles and gene-specific DNA methylation in blood-based DNA to develop putative screening markers for cancer. However, most of the studies have not yet been validated. In our study, we analyzed the promoter methylation of RASSF1A and ATM in peripheral blood DNA of 229 sporadic patients and 151 healthy controls by the MassARRAY EpiTYPER assay. There were no significant differences in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. Furthermore, we performed the Infinium HumanMethylation450 BeadChip (450K) array analysis using 48 sporadic BC cases and 48 healthy controls (cases and controls are the same from those of the MassARRAY EpiTYPER assay) and made a comparison with the published data. No significant differences were presented in DNA methylation levels of RASSF1A and ATM between the sporadic BC cases and the healthy controls. So far, the evidence for powerful blood-based methylation markers is still limited and the identified markers need to be further validated.
000135951 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000135951 588__ $$aDataset connected to CrossRef, PubMed,
000135951 7001_ $$0P:(DE-He78)a4faf5b3a2d51ffde33f91590be3d539$$aTang, Qiuqiong$$b1$$udkfz
000135951 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b2$$udkfz
000135951 7001_ $$00000-0003-2236-6604$$aGündert, Melanie$$b3
000135951 7001_ $$0P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aCuk, Katarina$$b4$$udkfz
000135951 7001_ $$aSchott, Sarah$$b5
000135951 7001_ $$aHeil, Jörg$$b6
000135951 7001_ $$aGolatta, Michael$$b7
000135951 7001_ $$aSohn, Christof$$b8
000135951 7001_ $$aSchneeweiss, Andreas$$b9
000135951 7001_ $$0P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aBurwinkel, Barbara$$b10$$eLast author$$udkfz
000135951 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms19030900$$gVol. 19, no. 3, p. 900 -$$n3$$p900 -$$tInternational journal of molecular sciences$$v19$$x1422-0067$$y2018
000135951 909CO $$ooai:inrepo02.dkfz.de:135951$$pVDB
000135951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000135951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a4faf5b3a2d51ffde33f91590be3d539$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000135951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000135951 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2236-6604$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000135951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000135951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000135951 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000135951 9141_ $$y2018
000135951 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2015
000135951 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000135951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000135951 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000135951 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000135951 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000135951 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000135951 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000135951 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000135951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000135951 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000135951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000135951 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000135951 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000135951 9201_ $$0I:(DE-He78)C080-20160331$$kC080$$lMolekulare Epidemiologie$$x0
000135951 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000135951 980__ $$ajournal
000135951 980__ $$aVDB
000135951 980__ $$aI:(DE-He78)C080-20160331
000135951 980__ $$aI:(DE-He78)C060-20160331
000135951 980__ $$aUNRESTRICTED